Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Application of immunosignatures to the assessment of Alzheimer's disease.

Restrepo L, Stafford P, Magee DM, Johnston SA.

Ann Neurol. 2011 Aug;70(2):286-95. doi: 10.1002/ana.22405.

PMID:
21823156
2.

Feasibility of an early Alzheimer's disease immunosignature diagnostic test.

Restrepo L, Stafford P, Johnston SA.

J Neuroimmunol. 2013 Jan 15;254(1-2):154-60. doi: 10.1016/j.jneuroim.2012.09.014. Epub 2012 Oct 18.

PMID:
23084373
3.

Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.

Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Pavlovic J, Wollmer MA, Nitsch RM, Moelling K.

J Mol Med (Berl). 2004 Oct;82(10):706-14.

PMID:
15241501
4.

[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].

Robert PH, Schuck S, Dubois B, Lépine JP, Gallarda T, Olié JP, Goni S, Troy S.

Encephale. 2003 May-Jun;29(3 Pt 1):266-72. French.

PMID:
12876552
5.

Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2010;21(1):291-301. doi: 10.3233/JAD-2010-091501.

PMID:
20421698
6.

Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.

Meli G, Visintin M, Cannistraci I, Cattaneo A.

J Mol Biol. 2009 Apr 3;387(3):584-606. doi: 10.1016/j.jmb.2009.01.061. Epub 2009 Feb 4.

PMID:
19361429
7.

Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.

Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J.

J Chem Neuroanat. 2010 Sep;40(1):82-92. doi: 10.1016/j.jchemneu.2010.03.006. Epub 2010 Mar 25.

PMID:
20347032
8.

Antibody-based therapy in Alzheimer's disease.

Pul R, Dodel R, Stangel M.

Expert Opin Biol Ther. 2011 Mar;11(3):343-57. doi: 10.1517/14712598.2011.552884. Epub 2011 Jan 25. Review.

PMID:
21261567
9.

APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.

Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE.

Biochemistry. 2002 Jan 22;41(3):922-8.

PMID:
11790115
10.

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development.

Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, Woodward J, Guo Z, Fu W, Kryscio R, Wekstein D, Smith C, Markesbery WR, Mattson MP.

Neuromolecular Med. 2003;3(1):29-39.

PMID:
12665674
11.

Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.

Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM.

J Neurochem. 2007 Aug;102(4):1053-63. Epub 2007 Apr 30.

12.

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12145-50. doi: 10.1073/pnas.0904866106. Epub 2009 Jul 6.

13.

Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.

Nemirovsky A, Fisher Y, Baron R, Cohen IR, Monsonego A.

Vaccine. 2011 May 23;29(23):4043-50. doi: 10.1016/j.vaccine.2011.03.033. Epub 2011 Apr 5.

PMID:
21473952
14.

Transgenic mouse models of Alzheimer's disease: phenotype and application.

Higgins GA, Jacobsen H.

Behav Pharmacol. 2003 Sep;14(5-6):419-38. Review.

PMID:
14501255
15.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
16.

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M.

J Neurosci. 2011 Apr 13;31(15):5847-54. doi: 10.1523/JNEUROSCI.4401-10.2011.

17.

Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.

Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA.

Rapid Commun Mass Spectrom. 2006;20(24):3723-35.

PMID:
17117458
18.

I32E and V36K double mutation in beta2-sheet abrogates amyloid beta peptide toxicity.

Subramanian S, Mishra PK, Bandopadhyay D.

Indian J Exp Biol. 2010 Nov;48(11):1098-102.

PMID:
21117449
19.

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease.

Holtzman DM, Bales KR, Paul SM, DeMattos RB.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1603-13. Review.

PMID:
12453677
20.

Supplemental Content

Support Center